A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

Cancer

Volumn 82, Issue 12, 1998, Pages 2321-2325

  Sanz Altamira, Pedro M ^a   Ferrante, Karen ^a   Jenkins, Roger L ^a   Lewis, W David ^a   Huberman, Mark S ^a   Stuart, Keith E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

5 Fluorouracil; Biliary tree carcinoma; Carboplatin; Cholangiocarcinoma; Leucovorin; Phase II trial

Indexed keywords

CARBOPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; CARBOPLATIN; CHOLANGIOCARCINOMA; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 0032526183     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980615)82:12<2321::AID-CNCR4>3.0.CO;2-V     Document Type: Article

References (23)

1. Pitt HA, Grochow LB, Abrams RA. Cancer of the biliary tree. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: Lippincott-Raven, 1997:1114-28.
2. Hamrick RE, Liner FJ, Hastings PR, Cohn I. Primary carcinoma of the gallbladder. Ann Surg 1982;195:270-3.
3. Roberts JW, Daugherty SF. Primary carcinoma of the gallbladder. Surg Clin North Am 1986;66:743-9.
4. Evander A, Fredlund P, Hoevels J, Ihse I, Bengmark S. Evaluation of aggressive surgery for carcinoma of the extrahepatic bile ducts. Ann Surg 1980;191:23-9.
5. Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CHN, et al. Phase II trial of mitomycin C in advanced gallbladder and biliary tree carcinoma. An EORTC Gastro-intestinal Tract Cooperative Group Study. Ann Oncol 1993; 4:607-9.
6. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T. Comparison of 5-fluorouracil, doxorubicin, and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology 1994;51: 396-400.
7. Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994;51:515-7.
8. Rougier P, Fandi A, Ducreux M, Fandi L, Fabri MC, Zarba J, et al. Demonstrated efficiency of 5-fluorouracil continuous infusion and cisplatin in patients with advanced biliary tract carcinoma. Proc Am Soc Clin Oncol 1995;14:205.
9. Di Lauro L, Carpano S, Campomolla E, Conti F, Rinaldi M, Lopez M, et al. Cisplatin, epirubicin, and fluorouracil (PEF) for advanced biliary tract carcinoma. Proc Am Soc Clin Oncol 1997;16:287a.
10. Patt YZ, Jones D, Markowitz A, Charnsangavej C. Phase II trial of 5-FU and alpha-interferon in biliary tract cancers. Proc Am Soc Clin Oncol 1995;14:203.
11. Kajanti M, Pyrhönen S. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of extrahepatic biliary system: a phase II study. Am J Clin Oncol 1994;17:223-6.
12. Jones DV, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996;14:2306-10.
13. Mezger J, Sauerbruch T, Ko Y, Wolter H, Funk C. Phase II trial of gemcitabine in biliary tract cancers. Proc Am Soc Clin Oncol 1997;16:297a.
14. Oberfield RA, Rossi RL. The role of chemotherapy in the treatment of bile duct cancer. World J Surg 1988;12:105-8.
15. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984;2:1245-8.
16. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidilate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13:471-80.
17. Danenberg PV, Lockshin A. Thymidylate synthetase-substrate complex formation. Mol Cell Biochem 1982;43:49-57.
18. Yin MB, Zakrzewski SF, Hakala MT. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 1983;23:190-7.
19. Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986;46:1972-9.
20. Canetta R, Smaldone L, Bragman K, Rozencweig M. Clinical trials with carboplatin in other tumor types: adult and pediatric malignancies. In: Bunn PA, Canetta R, Ozols RF, Rozencweig M, editors. Carboplatin (JM-8). Current perspectives and future directions. Philadelphia: W.B. Saunders Company, 1990:345-52.
21. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984;54:965-9.
22. Isacoff WH, Botnick L, Tompkins R, Jacobs AD, Reber H, Taylor O. Treatment of patients with advanced tumors of the bile ducts with continuous infusion 5-fluorouracil in conjunction with calcium leucovorin, mitomycin C, and dipyridamole. Proc Am Soc Clin Oncol 1993;12:225.
23. Hall SW, Benjamin RS, Murphy WK, Valdivieso M, Bodey GP. Adriamycin, BCNU, Ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer 1979;44:2008-13.